A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome - Concepedia

Concepedia

Publication | Open Access

A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

DOI Full Paper Access

99

Citations

34

References

2019

Year

Helen Heussler, Jonathan Cohen, Natalie Silove, Nancy Tich, Marcel O. Bonn‐Miller, Wei Du, Carol O’Neill, Terri Sebree

Journal of Neurodevelopmental Disorders

References

	Year	Citations

Page 1